标题：晚期胰腺癌调强放疗同步吉西他滨化疗的临床观察

      作者：胡 伟 1，张 娟 2
    (1.荆州市中心医院肿瘤放疗中心，湖北 荆州 434020；
2.荆州市第一人民医院神经内科二区，湖北 荆州 434000)

      卷次： 2012年23卷8期

      【摘要】 目的 观察调强放疗同步吉西他滨化疗在晚期胰腺癌治疗上的效果。方法 选择我院诊疗的资
料齐全且得到病理确诊或影像学确诊的晚期胰腺癌患者共计90例，随机分成三组，放疗合并化疗组、单用放疗组
以及单用化疗组，分别给予调强放疗同步吉西他滨化疗、单纯放疗以及单用吉西他滨化疗治疗。观察三组的治
疗效果，分别将单独放疗组、单独化疗组与放疗合并化疗组进行比较。同时对患者随访1~3年，比较三组患者的
1年生存率以及2年生存率。结果 放疗合并化疗组总有效人数19例(63.33%)，单独放疗组12例(40%)，单独化
疗组11例(36.67%)，治疗有效率上放疗联合化疗组明显高于其余两组(P＜0.05)。放疗联合化疗的患者1年生存
率达到46.67%，2年生存率达到23.33%；单用放疗组患者1年生存率为33.33%，2年生存率为3.33%；单用化疗组
患者1年生存率为26.67%，2年生存率为0%，结果显示放疗合并化疗组治疗后1年及2年生存率明显高于其余两
组(P<0.05)。结论 调强放疗同步吉西他滨化疗的疗效高于单独使用调强放疗或者单独使用吉西他滨化疗的疗
效，值得临床推广。

      【关键词】 晚期胰腺癌；吉西他滨；放疗；化疗；1年生存率；2年生存率

      【中图分类号】 R735.9 【文献标识码】 A 【文章编号】 1003—6350(2012)08—021—03<

br>Clinical observation on the effect of three dimensional-conformal radiotherapy combined with Gemcitabine
chemotherapy for advanced pancreatic cancers.
HU Wei 1*, ZHANG Juan 2. 1. Radiotherapy Center, the Central Hos-
pital of Jingzhou City, Jingzhou 434020, Hubei, CHINA; 2. The Second Department of Neurology, the First People’s Hos-
pital of Jingzhou City, Jingzhou 434000, Hubei, CHINA

【Abstract】 Objective To observe the clinical effect of three dimensional-conformal radiotherapy (3DCRT)
combined with Gemcitabine chemotherapy in the treatment of advanced pancreatic cancer. Methods Ninety patients
with advanced pancreatic cancer were randomly divided into three groups: radiotherapy combined with chemotherapy
group (received 3DCRT combined with Gemcitabine chemotherapy), single radiotherapy group (received 3DCRT),
and single chemotherapy group (received Gemcitabine chemotherapy). The clinical effect was observed and compared
between the three groups. All the patients were followed up for 1~3 years. The 1-year survival rate and 2-year surviv-
al rate were compared between the three groups. Results The treatment was effective in 19 cases (63.33%) in the ra-
diotherapy combined with chemotherapy group, which was significantly higher than the other two groups: 12 cases
(40%) in the single radiotherapy group and 11 cases (36.67%) in the single chemotherapy group. The 1-year survival
rate and 2-year survival rate in the radiotherapy combined with chemotherapy group reached 46.67% and 23.33%, sig-
nificantly higher than that in the other two groups (33.33% and 3.33% in the single radiotherapy group, 26.67% and
0% in the single chemotherapy group). Conclusion 3DCRT combined with Gemcitabine chemotherapy has better
clinical effect than radiotherapy alone or chemotherapy alone, which should be extended in clinical practice.

      【Key words】 Advanced pancreatic cancer; Gemcitabine; Radiotherapy; Chemotherapy; 1-year survival rate;